<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this review, we provide an overview of the physiological and pathophysiological epigenetic changes of <z:mpath ids='MPATH_458'>normal</z:mpath> cells and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells, and emphasize the achievements and the perspectives of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> epigenetic therapy </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> epigenetic alterations correspond foremost to hypermethylation of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes promotors, global DNA hypomethylation, and overexpression and activity of <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylases </plain></SENT>
<SENT sid="2" pm="."><plain>The purpose of epigenetic therapy is to revert the epigenetic alterations in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells and obtain the "<z:mpath ids='MPATH_458'>normal</z:mpath> epigenome" restoration </plain></SENT>
<SENT sid="3" pm="."><plain>Epigenetic targets in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy have focused on HDACs and DNMTs inhibition </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:chebi fb="0" ids="2038">azacitidine</z:chebi> and the <z:chebi fb="0" ids="50131">decitabine</z:chebi>, the vorinostat and the romidepsin were approved by US-FDA for treatment of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, and cutaneous T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Epigenetic and epigenomic changes in single or multiple genes have showed potential impact in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> as early detection, prognosis and predictive marks </plain></SENT>
<SENT sid="6" pm="."><plain>The epigenetic revolution has arrived for biology </plain></SENT>
<SENT sid="7" pm="."><plain>The significant progress in epigenetic studies have allowed us, to understand new looks in the <z:mp ids='MP_0001532'>physiology</z:mp> and pathophysiology of embryonic development, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and other <z:hpo ids='HP_0011010'>chronic</z:hpo> diseases </plain></SENT>
<SENT sid="8" pm="."><plain>Specific molecular epigenetic alterations in different <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> types, give us new strategies to design improved <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy </plain></SENT>
<SENT sid="9" pm="."><plain>The challenge for epigenetic investigators is design more specific epidrugs with lesser side effects </plain></SENT>
</text></document>